Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym013 in advanced epithelial malignancies
NCT02906670Phase 2Terminated
- Sponsor
- Symphogen
- Start
- Nov 2016
- Primary completion
- Jun 2019
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sym013 in carcinoma, sponsored by Symphogen. Started Nov 2016; status: terminated.
02
Drugs
sym013
03
Conditions
carcinoma
Beyond the preview
Go deeper on NCT02906670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906670.